The Global Health Body Raises Warning Over Critical Shortage of Weight-Loss Medications

Less than one in 10 people that would benefit from GLP-1 drugs such as Wegovy have access to them, states the World Health Organization as it issues its first guidance on the drugs.

Considering in excess of 1,000,000,000 people worldwide now living with obesity, it is urging increased and just availability to GLP-1 medication.

According to projections, in excess of 2,000,000,000 will be obese by 2030 if no action is taken.

"Our latest guidance recognises that excess weight is a chronic disease that can be managed with holistic and lifelong treatment," stated WHO director-general Tedros Adhanom Ghebreyesus.

High costs, insufficient output, and supply-chain constraints are major obstacles to widespread availability to the injections that can aid individuals in losing significant weight, says the body.

Skinny Jab Supply Crisis

Even in the present most favorable outlook, the production of GLP-1 therapies could only cover about 100 million people – under 10% of the global need, as stated by the WHO.

The guideline urges governments and firms to increase access, by approaches like voluntary licensing.

A patent on semaglutide – the main ingredient of a leading brand – is set to lapse in several countries in 2026.

The Way Weight-Loss Jabs Function

GLP-1 drugs mimick a biological compound to slow digestion, reduce hunger and enhance the sense of being full so individuals reduce food intake.

Individuals commonly see weight reduction within a few weeks of beginning the regular doses.

Research suggests patients may put most of the weight back on a year later of halting the drug, when their normal food cravings return.

Being carrying excess weight elevates your risk for experiencing health problems, such as diabetes, heart disease, brain attack, and certain malignancies.

Excess weight concerns people in countries worldwide and was responsible for over three and a half million fatalities worldwide in 2024, per the health agency.